Found: 18
Select item for more details and to access through your institution.
Evaluation of an Arthritis Communication Campaign to Promote Physical Activity in Two Cities.
- Published in:
- Health Promotion Practice, 2011, v. 12, n. 1, p. 116, doi. 10.1177/1524839909331554
- By:
- Publication type:
- Article
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes—Study for Monitoring Antimicrobial Resistance Trends, United States 2015–2017
- Published in:
- Clinical Infectious Diseases, 2021, v. 72, n. 12, p. 2112, doi. 10.1093/cid/ciaa381
- By:
- Publication type:
- Article
Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019.
- Published in:
- BMC Microbiology, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12866-021-02135-z
- By:
- Publication type:
- Article
Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards—SMART United States 2017–2019.
- Published in:
- Open Forum Infectious Diseases, 2021, v. 8, n. 7, p. 1, doi. 10.1093/ofid/ofab320
- By:
- Publication type:
- Article
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020.
- Published in:
- Brazilian Journal of Infectious Diseases, 2023, v. 27, n. 3, p. 1, doi. 10.1016/j.bjid.2023.102775
- By:
- Publication type:
- Article
Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013-2015.
- Published in:
- Brazilian Journal of Infectious Diseases, 2017, v. 21, n. 3, p. 343, doi. 10.1016/j.bjid.2017.03.006
- By:
- Publication type:
- Article
Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico—SMART 2017–2021.
- Published in:
- JAC-Antimicrobial Resistance, 2024, v. 6, n. 3, p. 1, doi. 10.1093/jacamr/dlae077
- By:
- Publication type:
- Article
Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates—SMART United States 2019–21.
- Published in:
- JAC-Antimicrobial Resistance, 2024, v. 6, n. 1, p. 1, doi. 10.1093/jacamr/dlad152
- By:
- Publication type:
- Article
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)--SMART 2017-21.
- Published in:
- JAC-Antimicrobial Resistance, 2023, v. 5, n. 4, p. 1, doi. 10.1093/jacamr/dlad098
- By:
- Publication type:
- Article
Susceptibility profile and β-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam--SMART 2016-21.
- Published in:
- JAC-Antimicrobial Resistance, 2023, v. 5, n. 3, p. 1, doi. 10.1093/jacamr/dlad080
- By:
- Publication type:
- Article
In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018-20
- Published in:
- JAC-Antimicrobial Resistance, 2023, v. 5, n. 1, p. 1, doi. 10.1093/jacamr/dlad003
- By:
- Publication type:
- Article
In Vitro Activity of Imipenem/Relebactam Against Gram-Negative Bacilli from Pediatric Patients—Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program 2015–2017.
- Published in:
- Journal of the Pediatric Infectious Diseases Society, 2021, v. 10, n. 3, p. 274, doi. 10.1093/jpids/piaa056
- By:
- Publication type:
- Article
Epidemiology and Antimicrobial Susceptibility of Gram-Negative Pathogens Causing Intra-abdominal Infections in Pediatric Patients in Europe--SMART 2011-2014.
- Published in:
- Journal of the Pediatric Infectious Diseases Society, 2017, v. 6, n. 1, p. 72, doi. 10.1093/jpids/piv109
- By:
- Publication type:
- Article
Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.
- Published in:
- 2019
- By:
- Publication type:
- journal article
In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy—SMART 2017–2021.
- Published in:
- European Journal of Clinical Microbiology & Infectious Diseases, 2024, v. 43, n. 7, p. 1343, doi. 10.1007/s10096-024-04756-4
- By:
- Publication type:
- Article
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland—SMART 2017–2020.
- Published in:
- European Journal of Clinical Microbiology & Infectious Diseases, 2023, v. 42, n. 3, p. 365, doi. 10.1007/s10096-023-04549-1
- By:
- Publication type:
- Article
Activity of Ertapenem against Enterobacteriaceae in seven global regions—SMART 2012-2016.
- Published in:
- European Journal of Clinical Microbiology & Infectious Diseases, 2018, v. 37, n. 8, p. 1481, doi. 10.1007/s10096-018-3274-y
- By:
- Publication type:
- Article